Weekly Recap: Pipeline and oral GLP-1 scale-up and CagriSema FDA timeline
Novo Nordisk A/S Sponsored ADR Class B (OMXCOP:NOVO_B) is executing a cost—cutting, multi—blockbuster push—10x oral GLP—1 capacity, CagriSema launch and Wegovy expansion—while investors fret over semaglutide patent cliffs, competitive trial setbacks and an 18% YTD selloff.Previous Week RecapThis is…